Soticlestat's potential in treating Lennox-Gastaut and Drave...
Soticlestat's potential in treating Lennox-Gastaut and Dravet syndromes is backed by Ovid and Ligand's deal. Ligand sees the deal aligning with its strategy of investing in solutions answering high unmet needs, promising high-margin growth for its investors.
Press Release: Ovid Therapeutics and Ligand Pharmaceuticals Enter Into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway Into 2026
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment